We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Drug pusher

30 January 2009 By Jeffrey Goldfarb

The Swiss drugs group has gone hostile, and cut the price, to land the 44% of Genentech it doesn t own. Fast cash even a little less of it might tempt minorities. But Roche s aggression suggests a strong desire to get the deal done. Holders might just want to play it cool.

This content is for Subscribers only

 

Drug pusher

30 January 2009 By Jeffrey Goldfarb

The Swiss drugs group has gone hostile, and cut the price, to land the 44% of Genentech it doesn t own. Fast cash even a little less of it might tempt minorities. But Roche s aggression suggests a strong desire to get the deal done. Holders might just want to play it cool.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)